cancer pain
DESCRIPTION
Here areTRANSCRIPT
Cancer Pain ManagementSuzana Makowski, MD MMM FACP FAAHPM
Prevalence of Cancer Pain
• 50 to 90 percent of oncology inpatients report breakthrough pain
• 35 percent of community based oncology practices patients report breakthrough pain
• 1 in 3 patients with active cancer report pain• 3 out of 4 of patients with advanced cancer report pain
Common Causes
• Bone metastases• Visceral metastases• Immobility• Neuropathic pain• Soft tissue• Constipation• Esophagitis• Lymphedema• Muscle cramps• Chronic postoperative scar
• Adapted from Twycross R, Harcourt J, Bergl S: A survey of pain in patients with advanced cancer. J Pain Symptom Manage 1996;12:273-282.
Effects of under treated pain
Physical Emotional Existential• Increased catabolic demands:
poor wound healing, weakness, muscle breakdown
• Decreased limb movement: increased risk of DVT/PE
• Respiratory effects: shallow breathing, tachypnea, cough suppression increasing risk of pneumonia and atelectasis
• Sodium and water retention Decreased gastrointestinal mobility
• Tachycardia and elevated blood pressure
• Decreased functional status• Increased chronic pain
DepressionAnxietyDecreased intimacySuicidality
Suffering – “why me?”
Effects of under treated pain
Barriers to Pain Control
• System barriers to treating pain• Clinical,• Patient-related• System-related
• Racial and ethnic barriers exist• Language• Perceptions
• Concern about addiction• Differences between addiction, • dependence, • tolerance & • pseudoaddiction
Pain Assessment
Intensity • Location • Quality • Timeline • Alleviating factors • Meds tried
Intensity
What about for patients who cannot self-report?
Pain Quality
Category Cause Symptom Examples
Physiologic
Brief exposure to a noxious stimulus
Rapid yet brief pain perception
Touching a pin or hot object
Nociceptive/inflammatory
Somatic or visceral tissue injury with mediators having an impact on intact nervous tissue
Moderate to severe pain, described as crushing or stabbing
Surgical pain, traumatic pain, sickle cell crisis
Neuropathic Damage or dysfunction of peripheral nerves or CNS
Severe lancinating, burning or electrical shock like pain
Neuropathy, CRPS. Postherpetic Neuralgia
MixedCombined somatic and nervous tissue injury
Combinations of symptoms; soft tissue plus radicular pain
Low back pain, back surgery pain
Timeline
Prior medications & other tx
• What worked?• What doses?• What side
effects?
Side effects
Common
• Constipation• Nausea• Sleepiness/somnolence• Pruritus• Myoclonus
Rare
• Respiratory suppression• Neurotoxicity• Seizures
Opioid Pharmacology
Opioid Pharmacology
Short-acting Long-acting
• Hydrocodone/APAP• Oxycodone +/- APAP• Morphine• Hydromorphone• Oral transmucosal fentanyl
• Transdermal fentanyl• methadone• morphine ER• oxycodone ER
• Cmax ~ 45 min• T1/2 ~ 4 hours• Except fentanyl
Cmax and T1/2 vary based on formulation and drug
Opioid pharmacology
• Conjugated by liver• 90-95% excreted in urine• Dehydration, renal failure, severe hepatic failure• Decrease interval/dosing size• If oliguria/anuria• STOP routine dosing (basal rate) of morphine
• Use ONLY PRN
Opioid Pharmacology
What is the half life (range) for opioids?• 2-4 hours
How many half lives to get to steady state? • 4-5
What do you base your scheduled dosing on: Cmax or T1/2?
• T1/2
What do you base your breakthrough dosing on: Cmax or T1/2?
• Cmax
Equianalgesic dosing
WHO Step-Ladder
What is the challenge with Step 2 of the ladder?
Case – part 1 - outpatient
Hector G - 65 yo man with colon cancer and bone metastases
Your colleague first started Mr. G on hydrocodone 5 mg + acetaminophen 325 mg one tablet by mouth every 4 hours prn for his hip and rib pain. He also ordered senna + docusate 2 tabs po qday to prevent opioid‐induced constipation.
Today, he tells you he is taking the Vicodin 1 tablet every 4 hours around the clock (including at night). His pain is generally constant, aching and he rates it as 5/10, but worsens to 8/10 with certain positions and movements.
• How will you titrate his opioid pain medication?
Case – Part 1
• Convert from Vicodin to Morphine• How to convert to a combination of long- and short-
acting morphine (the latter for breakthrough pain)?• What co-analgesics and other treatments might you
choose?
Case – Part 2 – NPO inpatient
• Hector comes to hospital for a procedure. He is made NPO. His pain has been well managed. How do you manage his pain?
• Home regimen: MSContin 30mg BID, Roxanol 10mg q2 hours prn, requiring 2 – 4 doses per day.
• What if he were on Oxycodone/Oxycontin instead?
Case – part 3
• Mr. G presents to the ER after several days of escalating hip and rib pain, despite taking the maximum dose of morphine he was prescribed as an outpatient. “I can’t take it anymore.” You admit him for pain management while trying to treat his escalating pain.
• Home medications: MSContin PO 30mg bid, Morphine liquid 10mg PO q2 hours prn (taking every dose)
In addition to imaging him, calling radiation oncology for evaluation, how do you manage his pain?
Pain crisis
• This is as much of a crisis as a code (JAMA 2008;299(12):1457-1467. doi: 10.1001/jama.299.12.1457)
• http://jama.ama-assn.org/content/299/12/1457.full.pdf
Advanced pain techniques
Non-interventional
• Methadone (opioid + NMDA)
• Ketamine (NMDA) infusion
• Lidocaine infusion
Interventional
• Nerve blocks• Intrathecal pain pumps
Pain at End-of-Life
• Choosing to be CMO does not automatically increase opioid requirement
• Caution with renal failure
CMO ≠ Continuous Morphine Only
Summary: Top 10
• Pain is common in cancer. Undertreated pain worsens prognosis
• On a good day, patients should not need PRNs, and on a bad day, should not need it more than 4 times per day.
• When converting to IV from PO – don’t forget to include the long-acting opioid.
• Opioid conversion is not mysterious• Pain Crises is as serious as a code• Methadone is a great drug – but is complicated• Avoid morphine and hydromorphone in renal failure • Match pain pattern with opioid pharmacology• CMO ≠ continuous morphine only• We’re here to help
Free CME from NCI
• https://cissecure.nci.nih.gov/ncipubs/detail.aspx?prodid=Q014